These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6979819)

  • 1. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of the coagulant activity and surface binding of high molecular weight kininogen.
    Colman RW; Silver LD; Purdon AD; Chang JJ; Scott CF
    Trans Assoc Am Physicians; 1984; 97():113-23. PubMed ID: 6336014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
    Scott CF; Schapira M; James HL; Cohen AB; Colman RW
    J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW
    Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of high molecular weight kininogen in contact activation.
    van Iwaarden F; Bouma BN
    Semin Thromb Hemost; 1987 Jan; 13(1):15-24. PubMed ID: 2436301
    [No Abstract]   [Full Text] [Related]  

  • 6. Conformation of high molecular weight kininogen: effects of kallikrein and factor XIa cleavage.
    Villanueva GB; Leung L; Bradford H; Colman RW
    Biochem Biophys Res Commun; 1989 Jan; 158(1):72-9. PubMed ID: 2783551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.
    Scott CF; Carrell RW; Glaser CB; Lewis JH; Colman RW
    Trans Assoc Am Physicians; 1985; 98():344-51. PubMed ID: 3879844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor.
    Walsh PN; Sinha D; Kueppers F; Seaman FS; Blankstein KB
    J Clin Invest; 1987 Dec; 80(6):1578-86. PubMed ID: 3500185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX.
    Baglia FA; Sinha D; Walsh PN
    Blood; 1989 Jul; 74(1):244-51. PubMed ID: 2665835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells.
    Berrettini M; Schleef RR; Heeb MJ; Hopmeier P; Griffin JH
    J Biol Chem; 1992 Oct; 267(28):19833-9. PubMed ID: 1400299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
    McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
    Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of high molecular weight kininogen in modulating the inactivation of human plasma kallikrein by plasma protease inhibitors.
    Schapira M; James A; Scott CF; Kueppers F; James HL; Cohen AB; Colman RW
    Adv Exp Med Biol; 1983; 156():131-41. PubMed ID: 6190364
    [No Abstract]   [Full Text] [Related]  

  • 13. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function.
    Scott CF; Silver LD; Purdon AD; Colman RW
    J Biol Chem; 1985 Sep; 260(19):10856-63. PubMed ID: 3875612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of factor IX by factor XIa--a spectrophotometric assay for factor IX in human plasma.
    Tans G; Janssen-Claessen T; van Dieijen G; Hemker HC; Rosing J
    Thromb Haemost; 1982 Oct; 48(2):127-32. PubMed ID: 6983739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human salivary kallikrein: reactivities to human plasma kininogens and proteinase inhibitors.
    Sakamoto W; Yoshikawa K; Uehara S; Nishikaze O
    J Biochem; 1983 Mar; 93(3):833-8. PubMed ID: 6553577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
    Tans G; Janssen-Claessen T; Rosing J; Griffin JH
    Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activation of human factor IX.
    Osterud B; Laake K; Prydz H
    Thromb Diath Haemorrh; 1975 Jun; 33(3):553-63. PubMed ID: 239460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-mediated trigger mechanisms in the contact phase of blood coagulation.
    Walsh PN
    Semin Thromb Hemost; 1987 Jan; 13(1):86-94. PubMed ID: 3031818
    [No Abstract]   [Full Text] [Related]  

  • 19. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain.
    Page JD; You JL; Harris RB; Colman RW
    Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major inhibitors of the contact phase coagulation factors.
    Schapira M
    Semin Thromb Hemost; 1987 Jan; 13(1):69-78. PubMed ID: 2436302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.